There is no single best medication for type 2 diabetes. The right choice depends on your blood sugar levels, body weight, kidney function, heart health, and what you can afford. That said, metformin remains the most widely used starting medication, and newer drug classes like GLP-1 receptor agonists and SGLT2 inhibitors have changed the landscape by offering benefits well beyond blood sugar control.
Current guidelines from the American Diabetes Association recommend starting medication at the time of diagnosis, often in combination rather than one drug at a time. The old approach of trying metformin alone, waiting, then adding a second drug is increasingly seen as outdated.
Why Metformin Is Still the Starting Point
Metformin has been the default first-line treatment for type 2 diabetes for decades, and for good reason. It lowers blood sugar effectively, carries a very low risk of causing dangerously low blood sugar (hypoglycemia), and costs as little as $4 a month with insurance or $4 to $15 without it. It’s available as a generic, and virtually every insurance plan covers it.
The standard starting dose is 500 mg twice a day with meals, or 850 mg once a day with breakfast. Your doctor will gradually increase the dose over weeks until your blood sugar reaches its target. An extended-release version, taken once daily with dinner, tends to cause fewer stomach issues. Nausea, bloating, and diarrhea are the most common side effects, and they usually improve within the first few weeks, especially if you take it with food and increase the dose slowly.
Metformin is safe for most people, but kidney function matters. It’s considered safe when your estimated kidney filtration rate (eGFR) is above 45. Below 45, the dose should be reduced. Below 30, or if you’re on dialysis, it should be stopped entirely.
GLP-1 Receptor Agonists: Blood Sugar and Weight Loss
GLP-1 receptor agonists are injectable medications that have become a cornerstone of type 2 diabetes treatment. They work by mimicking a gut hormone that signals your pancreas to release insulin after meals, slows digestion, and reduces appetite. The result is lower blood sugar and significant weight loss, a combination that no older diabetes drug can match.
Most people on a GLP-1 agonist see their A1C drop by 0.5 to 1.5 percentage points. In head-to-head trials, semaglutide (the active ingredient in Ozempic) reduced A1C by about 1.86%. The ADA now recommends GLP-1 agonists over insulin for most adults with type 2 diabetes who don’t have signs of insulin deficiency, a notable shift from earlier guidelines.
The main drawback is cost. Without insurance, a month’s supply of semaglutide can run $1,000 to $1,400. Even with insurance, copays range from $25 to $200 per month. Coverage varies widely, and some plans impose prior authorization requirements or step therapy rules that require you to try cheaper drugs first. Nausea is the most common side effect, especially during the first few weeks as your dose ramps up.
Tirzepatide: The Newest and Most Potent Option
Tirzepatide is a newer injectable that targets two gut hormones instead of one. In clinical trials comparing it directly to semaglutide, tirzepatide consistently delivered greater reductions in both blood sugar and body weight. In the SURPASS-2 trial, tirzepatide lowered A1C by 2.01 to 2.30 percentage points compared to semaglutide’s 1.86 points. Weight loss was also substantially larger: participants lost 7.6 to 11.2 kg on tirzepatide versus 5.7 kg on semaglutide.
In obesity-focused trials, tirzepatide produced roughly 20% body weight loss compared to about 14% with semaglutide. Half of people on tirzepatide lost at least 20% of their body weight, compared to about a quarter on semaglutide. Tirzepatide also showed stronger improvements in blood pressure, triglycerides, and waist circumference. Like GLP-1 agonists, it’s expensive and carries similar gastrointestinal side effects during dose escalation.
SGLT2 Inhibitors: Heart and Kidney Protection
SGLT2 inhibitors work by blocking sugar reabsorption in the kidneys, causing excess glucose to leave the body through urine. They lower A1C modestly, but their real value lies in protecting the heart and kidneys. These drugs carry a Class 1a recommendation (the strongest possible) for managing heart failure with reduced pumping ability, regardless of whether the patient has diabetes at all. They also slow chronic kidney disease progression in people with or without diabetes.
If you have type 2 diabetes along with heart failure or kidney disease, an SGLT2 inhibitor is likely part of your treatment plan no matter what your blood sugar looks like. These medications can be continued even when kidney filtration drops below 30, as long as dialysis isn’t imminent and the drug is well tolerated. Common side effects include urinary tract infections and genital yeast infections, both related to the increased sugar in the urine.
DPP-4 Inhibitors: A Milder Alternative
DPP-4 inhibitors are oral pills that work through a similar pathway as GLP-1 agonists but with a weaker effect. They typically lower A1C by 0.5 to 1.0 percentage points. They don’t cause weight loss, but they also don’t cause weight gain, and they carry a low risk of hypoglycemia. They’re well tolerated with few side effects, making them a reasonable option for people who can’t take other medications or who need modest additional blood sugar lowering without injectable drugs.
Why Early Combination Therapy Works Better
The traditional approach to diabetes treatment has been stepwise: start one drug, wait to see if it works, then add another. This sounds logical but often leads to long delays before a second medication is added, a problem researchers call “clinical inertia.” During those months or years of suboptimal blood sugar control, damage to blood vessels, nerves, and organs is already accumulating.
A large meta-analysis of over 24,000 participants found that starting two medications together from the beginning produced significantly better outcomes. Early combination therapy lowered A1C by an additional 0.49 percentage points compared to the stepwise approach. More striking, the time before treatment stopped working nearly doubled, from about 36 months with stepwise therapy to nearly 62 months with early combination. The combination approach also preserved insulin-producing beta cell function for about 3.5 years, while beta cells progressively declined with the one-at-a-time strategy. Patients on early combination therapy experienced 7.5 times fewer episodes of low blood sugar, lost about 5.3 kg more weight, and showed less buildup of plaque in their arteries.
The ADA’s current guidelines reflect this evidence, recommending combination therapy from the start to reach individualized blood sugar goals quickly rather than waiting for one drug to fail before adding another.
Choosing Based on Your Health Profile
The “best” medication depends heavily on what other health conditions you have and what matters most to you:
- If cost is a major concern: Metformin is by far the most affordable and is effective for most people as a foundation.
- If you need significant weight loss: Tirzepatide or semaglutide offer the largest reductions in body weight alongside strong blood sugar control.
- If you have heart failure: An SGLT2 inhibitor should be part of your regimen regardless of your A1C level.
- If you have chronic kidney disease: SGLT2 inhibitors slow disease progression. Metformin may need dose adjustment or discontinuation depending on your kidney function.
- If your A1C is above 10% or blood sugar is above 300 mg/dL: Insulin is typically needed right away, at least temporarily, regardless of what other medications you’re on.
For many people, the answer isn’t one medication but two or three working together. A common modern regimen might pair metformin with a GLP-1 agonist or SGLT2 inhibitor from the start, tailored to your specific cardiovascular risk, kidney health, weight goals, and budget.